1. 2022;25;E619-E627Sacral Nerve Stimulation in Patients With Refractory Pudendal Neuralgia
   Prospective Study
   Kai-kai Guo, MS, Long Wang, MD, Fang Liu, MS, Jie-jie Niu, MS, Chao Wang, MS, Shao-hua You, MD, Ze-guo Feng, MD, and Gui-jun Lu, MS.

BACKGROUND: Pudendal neuralgia (PN) is one of the most common forms of genital pain. Only 42.2% of PN patients respond to the first-line treatment. Novel neuromodulation techniques in the treatment of refractory PN patients are urgently required.

OBJECTIVES: The aim of this study was to evaluate the treatment effects and adverse events of
sacral nerve stimulation (SNS) for patients with refractory PN.

STUDY DESIGN: A prospective nonrandomized study.

SETTING: This prospective analysis included 33 patients who received the phase II surgical implantation.

METHODS: A total of 55 eligible PN patients were recruited for SNS treatment after informed consent, and 33 of 55 patients with a minimum 50% improvement were candidates for surgical implantation. Visual Analog Scale (VAS) scores, Self-rating Anxiety and Depression Scale, Quality of life score (SF-36), and sleep monitoring indicators before and after surgery were used to assess the effects of SNS on patients with refractory PN.

RESULTS: Thirty-three patients were included in the final analysis, involving 24 women and 9 men with a mean age of 49.5 years (26-70 years). There was a favorable decrease in pain severity (VAS scores) from 7.1 ± 1.1 at baseline to 6.1 ± 1.0 on postoperative day 1, and 2.8 ± 0.7 at 1 week, 1.7 ± 0.5 at 1 month, 1.1 ± 0.7 at 6 months, and 1.0 ± 0.6 at 12 months after surgery, respectively (P < 0.05). The mean score of each section of SF-36 after SNS was significantly higher than that at baseline (P < 0.05). Total sleep time and sleep time in each period were significantly prolonged after SNS implantation compared with that before surgery (6 months vs Pre, total: 5.32 ± 1.49 hours vs 3.66 ± 1.19 hours, deep: 2.52 ± 0.63 hours vs 1.36 ± 0.43 hours, light: 1.78 ± 0.42 hours vs 0.99 ± 0.30 hours, rapid eye movement: 1.41 ± 0.29 hours vs 0.89 ± 0.27 hours, P < 0.05). No serious device complications were reported during the follow-up period.

LIMITATIONS: Large-scale randomized clinical trials are warranted to evaluate the risk factors for prediction of refractory PN.

CONCLUSIONS: These data imply that SNS can have beneficial effects on patients with refractory PN.

KEY WORDS: Sacral nerve stimulation, refractory pudendal neuralgia, before-after study in the same patient